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Staphylococcus epidermidis  causes infections 
commonly associated with patients with indwelling 
medical devices due to its ability to form biofilms, 
bacterial structures attached to a surface and embed-
ded in a protective matrix. Cells within biofilms are 
known to be more resistant than free-floating plank-
tonic cells to the host immune response and also to 
antibiotic therapy often leading to relapsing infections 
[1]. Frequently, surgical removal of an infected device 
is required to resolve these infections, resulting in 
significant effects in a patient’s quality of life. Hence, 
preventative approaches are clearly needed to over-
come this challenge. 
 Antibodies have been shown to be one promis-
ing alternative to target surface-attached molecules 
and inhibit biofilm formation [2]. We have previously 
shown that human monoclonal antibodies (mAb) 
specific for poly-β-1,6-N-acetylglucosamine (PNAG) 
were effective in killing S. epidermidis in opsonopha-
gocytic in vitro assays, and in protecting the murine 
host against infection by PNAG-producing pathogens 
[3,4]. Since S. epidermidis  biofilm accumulation is 
mainly mediated by PNAG, it was hypothesized that 
the binding of this molecule by a specific mAb could 
impact biofilm accumulation, a process that has not 
previously been investigated. Here we tested the pre-
viously characterized mAb F598 [3], for inhibition of 
S. epidermidis  biofilm accumulation in vitro. Several 
concentrations of mAb F598 and the isotype control 
human mAb F429 (specific for the Pseudomonas aeru-
ginosa  alginate capsule) [5], were co-cultured with 
bacteria in static conditions for 1h at 37oC to allow 
antibody binding. Thereafter, cultures were incubated 
for 24h at 37oC with shaking at 250 rpm. Biofilm ac-
cumulation was then  quantified by the standard 
crystal violet staining [6].  
 Depending on the S. epidermidis strain used, the 
presence of mAb F598 had a differential effect on bio-
film accumulation. In the case of the ATCC strain 
RP62A we observed a 42% reduction in biofilm ac-
cumulation at the highest mAb concentration tested, 
while the clinical strains 1457 and M184 grown in the 
presence of mAb F598 had a dose-dependent increase 
of the biofilm accumulation. In the case of the 
PNAG-deficient,  ica-mutant strain 1457-M10, as ex-
pected, no significant effect was found on the biofilm 
biomass as no PNAG is produced. Furthermore, con-
trol mAb F429 had no significant effect on S. epider-
midis  biofilm accumulation. The results with the 
ica-mutant and mAb controls suggest altogether that 
the inhibitory or enhancing effect of the mAb is 
PNAG-dependent. As observed in other studies that 
have used antibodies specific for S. epidermidis surface 
molecules, the observed enhancement of biofilm for-
mation could be a result of increased PNAG expres-
sion caused by the early blockage of the synthesis of 
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this molecule [7]. On the other hand, the specificity of 
mAb F598 for epitopes on PNAG that do not require 
the N-acetyl groups on the glucosamine monomers 
may have contributed to the differential effects  in 
biofilm accumulation. These would thus depend on 
the level of PNAG acetylation of individual strains, 
ultimately, controlled by the IcaB extracellular 
deacetylase. Therefore, mAbs directed to other 
epitopes might be better suited for inhibition of in 
vitro biofilm accumulation. Additionally, the results 
presented here suggest that a difference between the 
effect of mAb F598 against PNAG-producing bacteria 
in animal models [3,4] and it efficiency at inhibiting in 
vitro static biofilm accumulation among different  S. 
epidermidis strains. Notably, many biofilms are formed 
under flow conditions and it is not clear to what ex-
tent shear stress from flow over in vivo biofilms con-
tributes to biofilm formation, and whether under 
those conditions the effect of mAb F598 might be dif-
ferent. While the stimulation of biofilm formation by 
S. epidermidis grown in vitro may raise questions re-
garding the usage of mAb F598 in vivo, the results do 
not necessarily exclude that mAb F598 could be effec-
tive in vivo against biofilm infections. 
 The majority of studies that reported strong bio-
film inhibition by monoclonal or polyclonal antibod-
ies used only a few strains in the assays [2,8], which 
could result in misleading interpretations. The find-
ings presented here further stress the necessity to use 
more than a few strains when testing the efficacy of 
new biofilm-inhibition strategies in order to ensure 
that the desired effect is observed in a representative 
number of clones of the species under study.  
 
 
 
Figure 1. Effect of mAb F598 specific to PNAG on S. epidermidis biofilm accumulation in vitro. The bars represent the median and the error 
bars the interquartile range of two independent experiments with quadruplicates for each concentration tested. Statistical significance was 
analyzed using Kruskal-Wallis one-way ANOVA Test and Dunn’s Multiple Comparisons Test with a 95% confidence level (GraphPad 
Prism version 6). *p<0.05, ** p<0.01 vs. TSB.   
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